ASCO GU24 special: Prof. Michael Hofman talks about a novel CA IX-targeting peptide

In this podcast, UROONCO RCC chief editor Dr. Carmen Mir (ES) interviews Prof. Michael Hofman from the Peter MacCallum Cancer Centre, Australia, on the results of his study “First-in-human safety, imaging and dosimetry of [68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC)”. Prof. Hofman discusses the data he presented at ASCO GU24 in San Francisco and suggests that these first-in-human findings with radiolabelled DPI-4452 are enco...